The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.

The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

[3] As per Forbes list of India’s 100 richest tycoons, dated 9 October 2024, the Reddy Family is ranked 87th with a net worth of $3.67 billion.

[citation needed] In 1999, Dr. Reddy's joined the Indian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.

They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive".

Reddy's research thrust focused on large niche areas in western markets – anti-cancer, anti-diabetes, cardiovascular and anti-infection drugs.

Reddy's merged Cheminor Drug Limited (CDL) with the primary aim of supplying active pharmaceutical ingredients to the technically demanding markets of North America and Europe.

[citation needed] Reddy's also started exploiting Para 4 filing as a strategy in bringing new drugs to the market at a faster pace.

With such high returns at stake, Reddy's was gambling on the success of the litigation; failure to win the case could have cost them millions of dollars, depending on the length of the trial.

Direct marketing under the Reddy's brand name represented a significant step in the company's efforts to build a strong and sustainable US generic business.

[citation needed] In 2015, Dr. Reddy's Laboratories bought the established brands of Belgian drugmaker UCB SA in South Asia for ₹8 billion ($128.38 million).

Funds raised from the initial public offering helped Reddy's move into international production and take over technology-based companies.

Under the terms of the agreement, ICICI Venture agreed to fund the development, registration and legal costs related to the commercialisation of ANDAs on a pre-determined basis.

In March 2002, Dr. Reddy's acquired BMS Laboratories, Beverley, and its wholly owned subsidiary Meridian Healthcare, for 14.81 million Euros.

], Dr. Reddy's entered into an R&D and commercialisation agreement with Argenta Discovery Ltd., a private drug development company based in the UK, for the treatment of chronic obstructive pulmonary disease (COPD).

The trials were conducted to study the safety and the pharmacokinetic profiles of the drug, which is intended for the treatment of atherosclerosis, a major cause of cardiovascular disorders.

Dr. Reddy's entered into a marketing agreement with Eurodrug Laboratories, a pharmaceutical company based in Netherlands, for improving its product portfolio for respiratory diseases.

[25] The first step in this program will be the launch of new patient friendly packaging for its top 25 best-selling brands, which will be rolled-out in a phased manner over the next six months.

The packaging has been designed such that blister packs would have extra space for brand name which ensures easy identification at the pharmacy, a tab at the bottom with expiry date clearly mentioned, and a pictorial representation of the time the medicine needs to be taken.

[26] In September 2005, Dr. Reddy's spun off its drug discovery and research wing into a separate company called Perlecan Pharma Private Limited.

[27] In 2009, the company did a U-turn and has handed over discovery research and related intellectual property to its Bangalore-based subsidiary, with the possibility of spinning it off as a different entity altogether.

[37] Dr. Reddy's Laboratories has faced significant criticism for its continued operations in Russia, despite the ongoing invasion of Ukraine and the imposition of international sanctions on the country.

While many global pharmaceutical companies have ceased or drastically reduced their presence in Russia in response to the invasion, Dr. Reddy's has remained steadfast in maintaining its business there.

[39][40][41] This decision has sparked widespread ethical concerns, as Dr. Reddy's has been accused of prioritizing profits over the human suffering caused by the war.

The company has also faced backlash for its ties to the Russian Direct Investment Fund (RDIF), which has backed the Sputnik V vaccine, further complicating its position amid the conflict.

By continuing operations in Russia, Dr. Reddy's is seen as contributing to the Russian economy and, by extension, supporting a regime responsible for war crimes and aggression.